Top Story

FDA approves Adakveo to reduce pain crises from sickle cell disease

FDA approves Adakveo to reduce pain crises from sickle cell disease
November 15, 2019

Trial of KD025 for chronic GVHD meets primary endpoint at interim analysis

November 12, 2019
A pivotal trial designed to assess KD025 for patients with pretreated chronic graft-versus-host disease met its primary endpoint of overall response rate, according to…
In the Journals

Antidepressant use linked to slightly increased risk for subdural hematoma

November 11, 2019
Use of selective and nonselective serotonin reuptake inhibitors appeared associated with a small increased risk for subdural hematoma, according to results of a…
FDA News

FDA approves Reblozyl for beta-thalassemia

November 8, 2019
The FDA today approved luspatercept-aamt to treat anemia in adults with beta-thalassemia who undergo regular red blood cell transfusions.
More Headlines »

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »

VIDEO: Immune-based approaches, autologous transplantation both essential in myeloma management

March 8, 2016
More »
Resource Centers

Innovations in Sickle Cell Disease: How the Latest Advances May Impact Clinical Decision-making

This activity is supported by an educational grant from Global Blood Therapeutics.

Sickle cell disease (SCD) is an inherited molecular condition whose clinical severity has extreme phenotypic…
More »